drugset / Trial / NCT00942968

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

NCT00942968

Phase 4 Completed 338 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.

Timeline

Start
2009-06
Primary completion
2012-03
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalteparin sodium Other / unclassified 200 iu/kg Subcutaneous

Indications